Noliterax (Indapamide, Perindopril Arginine)

Indapamide / Perindopril arginine, the active ingredients in Noliterax, are a diuretic and ACE inhibitor presented as an oral tablet for systemic use. They treat hypertension in adult patients. GNH USA supplies Noliterax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noliterax is used in the management of arterial hypertension, a major cardiovascular disease category. - Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Stage 1 hypertension: provides adequate blood‑pressure control when monotherapy is insufficient. - Stage 2 hypertension: contributes to target‑organ protection when combined with lifestyle measures.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first doses. - Headache: mild to moderate intensity, often resolves with continued therapy. - Cough: dry, non‑productive cough related to ACE inhibition. - Fatigue: general tiredness without specific cause. - Electrolyte imbalance: mild changes in sodium or potassium levels. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure causing fainting. - Renal impairment: worsening kidney function, particularly in patients with pre‑existing disease. - Hyperkalemia: elevated potassium that may cause cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Blood dyscrasias: rare blood cell abnormalities such as agranulocytosis.

Before prescribing Noliterax, clinicians should evaluate patient‑specific factors and monitor therapy closely. - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor serum sodium and potassium regularly. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Elderly: initiate at the lowest effective dose and titrate cautiously. - Concomitant ACE inhibitors or ARBs: avoid duplication to reduce risk of hyperkalemia. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Noliterax may interact with several medicines; careful review is required. Major Interactions (Avoid): - Lithium: increased lithium levels may cause toxicity. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and affect renal function. Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect. - Other diuretics: may enhance diuresis and electrolyte shifts. - Antidiabetic agents: potential for enhanced hypoglycaemia, monitor glucose.